Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Buccal Resveratrol Delivery System as a Potential New Concept for the Periodontitis Treatment

M. Paczkowska-Walendowska, J. Dvořák, N. Rosiak, E. Tykarska, E. Szymańska, K. Winnicka, MA. Ruchała, J. Cielecka-Piontek

. 2021 ; 13 (3) : . [pub] 20210320

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21018128

Grant support
778051 European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant
n/d Poznan University of Medical Sciences, under ProScience-Young Scientists grant

The health benefits of resveratrol have been proven to inhibit the development of numerous diseases. A frequent limitation in its use is a low bioavailability stemming from a poor solubility and fast enterohepatic metabolism. Thus, the aim of the research was to investigate the possibility to formulate mucoadhesive cyclodextrin- and xanthan gum-based buccal tablets in order to increase the solubility of resveratrol and to eliminate bypass enterohepatic metabolism. Systems of resveratrol with α-cyclodextrin (α-CD), β-cyclodextrin (β-CD), γ-cyclodextrin (γ-CD) and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) prepared by the dry mixing method (ratio 1:1) were selected for the of tablets where xanthan gum was used as a mucoadhesive agent. They were identified on the basis of PXRD, FT-IR analysis. Tablets F1 (with α-CD), F2 (with β-CD) and F3 (with γ-CD) were characterized by the highest compactibility as well as by favorable mucoadhesive properties. Resveratrol release from these tablets was delayed and controlled by diffusion. The tablets prepared in the course of this study appear to constitute promising resveratrol delivery systems and are recommended to increase the effectiveness of the treatment in many diseases, particularly periodontitis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018128
003      
CZ-PrNML
005      
20210729104136.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics13030417 $2 doi
035    __
$a (PubMed)33804630
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Paczkowska-Walendowska, Magdalena $u Department of Pharmacognosy, Poznan University of Medical Sciences, Święcickiego 4, 60-781 Poznań, Poland
245    10
$a Buccal Resveratrol Delivery System as a Potential New Concept for the Periodontitis Treatment / $c M. Paczkowska-Walendowska, J. Dvořák, N. Rosiak, E. Tykarska, E. Szymańska, K. Winnicka, MA. Ruchała, J. Cielecka-Piontek
520    9_
$a The health benefits of resveratrol have been proven to inhibit the development of numerous diseases. A frequent limitation in its use is a low bioavailability stemming from a poor solubility and fast enterohepatic metabolism. Thus, the aim of the research was to investigate the possibility to formulate mucoadhesive cyclodextrin- and xanthan gum-based buccal tablets in order to increase the solubility of resveratrol and to eliminate bypass enterohepatic metabolism. Systems of resveratrol with α-cyclodextrin (α-CD), β-cyclodextrin (β-CD), γ-cyclodextrin (γ-CD) and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) prepared by the dry mixing method (ratio 1:1) were selected for the of tablets where xanthan gum was used as a mucoadhesive agent. They were identified on the basis of PXRD, FT-IR analysis. Tablets F1 (with α-CD), F2 (with β-CD) and F3 (with γ-CD) were characterized by the highest compactibility as well as by favorable mucoadhesive properties. Resveratrol release from these tablets was delayed and controlled by diffusion. The tablets prepared in the course of this study appear to constitute promising resveratrol delivery systems and are recommended to increase the effectiveness of the treatment in many diseases, particularly periodontitis.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dvořák, Jakub $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague, Czech Republic $u Zentiva k.s., U Kabelovny 130, 102 37 Praha, Czech Republic
700    1_
$a Rosiak, Natalia $u Department of Pharmacognosy, Poznan University of Medical Sciences, Święcickiego 4, 60-781 Poznań, Poland
700    1_
$a Tykarska, Ewa $u Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland
700    1_
$a Szymańska, Emilia $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Białystok, Mickiewicza 2c, 15-222 Białystok, Poland
700    1_
$a Winnicka, Katarzyna $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Białystok, Mickiewicza 2c, 15-222 Białystok, Poland
700    1_
$a Ruchała, Marek A $u Department of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, Bukowska 70, 60-812 Poznań, Poland
700    1_
$a Cielecka-Piontek, Judyta $u Department of Pharmacognosy, Poznan University of Medical Sciences, Święcickiego 4, 60-781 Poznań, Poland
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 13, č. 3 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33804630 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104135 $b ABA008
999    __
$a ind $b bmc $g 1676549 $s 1138572
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 3 $e 20210320 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a 778051 $p European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant
GRA    __
$a n/d $p Poznan University of Medical Sciences, under ProScience-Young Scientists grant
LZP    __
$a Pubmed-20210726

Find record

Citation metrics

Archiving options